Financial Performance - For the fiscal year ending December 31, 2025, the company reported a loss attributable to shareholders of HKD 186.8 million, an increase of HKD 60.2 million compared to the previous year, primarily due to increased R&D expenses of HKD 66.5 million[3]. - After excluding one-time gains from the sale of vineyards in 2024 and special items in 2025, the company's after-tax net profit from its core business was HKD 130.8 million, an increase of HKD 42.6 million from 2024[3]. - Total revenue for the year ended December 31, 2025, was HKD 5,410,228,000, a decrease of 2.02% from HKD 5,522,674,000 in 2024[30]. - The annual loss for 2025 was HKD 188,447,000, compared to a loss of HKD 126,554,000 in 2024, with basic loss per share increasing to HKD 1.94 from HKD 1.32[30]. - The company reported a comprehensive income of HKD 122,703,000 for 2025, a recovery from a comprehensive loss of HKD 677,705,000 in 2024[31]. - The company reported a net loss of HKD 188,447 thousand for the year ending December 31, 2025, compared to a net loss of HKD 126,554 thousand in 2024[50]. Revenue Breakdown - Revenue from the healthcare products business was HKD 3.37 billion, a decrease of 2% compared to HKD 3.45 billion in 2024[15]. - Agricultural-related business recorded revenue of HKD 2.037 billion, down 2% from HKD 2.07 billion in 2024[17]. - Revenue from agricultural-related business was HKD 1,886,708,000, down from HKD 1,906,977,000 in 2024, representing a decline of 1.93%[40]. - Revenue from healthcare products decreased to HKD 3,371,935,000 from HKD 3,451,588,000, a drop of 2.31%[40]. - Revenue from the Asia-Pacific region was HKD 2,789,263 thousand in 2025, slightly down from HKD 2,813,144 thousand in 2024, a decrease of about 0.8%[52]. - Revenue from North America decreased to HKD 2,619,555 thousand in 2025 from HKD 2,708,189 thousand in 2024, a decline of approximately 3.3%[52]. Corporate Developments - The company underwent a significant corporate restructuring aimed at enhancing its pharmaceutical and diagnostic research capabilities and attracting more professional talent[4]. - In October 2025, RNAZ completed the acquisition of the melanoma cancer vaccine seviprotimut-L from the company, focusing on innovative immuno-oncology and RNA therapies for high-risk and late-stage cancers[4]. - The company established a wholly-owned subsidiary, Sequencio Therapeutics, to integrate all cancer vaccine R&D projects and focus on developing therapeutic cancer vaccines[6]. - The company strategically invested in Pharus Inc. to enhance early lung cancer detection accuracy using OncoSweep™ technology[13]. Research and Development - The group invested approximately HKD 320.6 million in research and development activities in 2025[26]. - DWTX announced positive interim results from a Phase 2b clinical trial of Halneuron®, showing a higher pain relief rate compared to the placebo group[8]. - RNAZ's main therapeutic candidate, TTX-MC138, completed Phase 1 clinical trials, achieving primary safety endpoints and preparing for Phase 2a trials in colorectal cancer patients[10]. - Sequencio is actively advancing multiple promising candidates into clinical trials, aiming to provide substantial clinical benefits to patients[12]. - The company is developing an AI-driven platform to optimize immunogenicity predictions, enhancing the design of cancer vaccines and improving clinical efficacy potential[12]. Financial Position - The group’s total assets as of December 31, 2025, were approximately HKD 11.84 billion, with net assets amounting to HKD 3.85 billion, equivalent to HKD 0.40 per share[22]. - The total bank borrowings amounted to HKD 6.0281 billion, with interest expenses totaling HKD 239.1 million for the year[22]. - The group’s net debt to total equity ratio was approximately 58.52% as of December 31, 2025[22]. - The company’s total equity increased to HKD 3,846,084,000 in 2025 from HKD 3,511,548,000 in 2024[33]. - The group reported a current liability exceeding current assets by HKD 461,180,000 as of December 31, 2025[36]. Employee and Operational Costs - Employee costs for the year were approximately HKD 1,238.4 million, a slight increase of 0.1% compared to the previous year[28]. - Financial expenses decreased to HKD 266,894,000 from HKD 337,184,000, a reduction of 20.7%[44]. - Tax expenses for 2025 amounted to HKD 170,436,000, significantly higher than HKD 35,072,000 in 2024[45]. Shareholder Information - The company did not recommend a final dividend for the year ending December 31, 2025 (2024: none)[47]. - The 2026 Annual General Meeting is scheduled for May 21, 2026[60]. - The record date for shareholders eligible to attend and vote at the 2026 Annual General Meeting is May 21, 2026[61]. - The company will suspend share transfer registration from May 18, 2026, to May 21, 2026, inclusive[61].
长江生命科技(00775) - 2025 - 年度业绩